Literature DB >> 42335

Pneumococcal infections after human bone-marrow transplantation.

D J Winston, G Schiffman, D C Wang, S A Feig, C H Lin, E L Marso, W G Ho, L S Young, R P Gale.   

Abstract

Seven of 26 long-term survivors (greater than 7 months post-transplant) of bone-marrow transplantation developed penicillin-sensitive pneumococcal infections more than 7 months after transplantation. One patient had two infections. Six of eight infections were associated with pneumococcal bacteremia, and Streptococcus pneumoniae type 6A was isolated in three cases. Two infections were fatal. All patients had normal nematopoietic function, and none was receiving immunosuppressive therapy. The development of pneumococcal infection was significantly associated with males and with abnormally low or high serum IGG and IgM levels but not with graft-versus-host disease. Serum opsonic activity for S. pneumoniae type 6A was decreased in six of the seven patients when compared to normal pooled serum in an in-vitro bactericidal assay. Four of the six patients with impaired opsonic activity had low serum antibody levels for S. pneumoniae type 6A capsular polysaccharide, while the other two patients had low serum CH100 complement activity. Bone-marrow transplant recipients have an increased susceptibility to pneumococcal infections and should be evaluated for prophylactic penicillin or pneumococcal vaccination.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 42335     DOI: 10.7326/0003-4819-91-6-835

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  20 in total

Review 1.  [Is the administration of immunoglobulins following bone marrow transplantation indicated?].

Authors:  H G Klingemann
Journal:  Klin Wochenschr       Date:  1987-09-15

Review 2.  Infection in the bone marrow transplant recipient and role of the microbiology laboratory in clinical transplantation.

Authors:  M T LaRocco; S J Burgert
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

3.  The transfer of antigen-specific humoral immunity from marrow donors to marrow recipients.

Authors:  L G Lum; M C Seigneuret; R Storb
Journal:  J Clin Immunol       Date:  1986-09       Impact factor: 8.317

4.  Human immune responses in vivo to protein (KLH) and polysaccharide (DNP-Ficoll) neoantigens: normal subjects compared with bone marrow transplant patients on cyclosporine.

Authors:  P L Amlot; A E Hayes; D Gray; E C Gordon-Smith; J H Humphrey
Journal:  Clin Exp Immunol       Date:  1986-04       Impact factor: 4.330

Review 5.  Intravenous immunoglobulin for secondary immunodeficiency.

Authors:  P L Yap
Journal:  Blut       Date:  1990-01

6.  Value of serum C-reactive protein measurement in the management of bone marrow transplant recipients. Part II: Late post-transplant period.

Authors:  S A Walker; P G Riches; T R Rogers; S White; J R Hobbs
Journal:  J Clin Pathol       Date:  1984-09       Impact factor: 3.411

7.  Preparation of human hyperimmune globulin to Haemophilus influenzae b, Streptococcus pneumoniae, and Neisseria meningitidis.

Authors:  G R Siber; D M Ambrosino; J McIver; T J Ervin; G Schiffman; S Sallan; G F Grady
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

8.  Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influence of graft versus host reaction.

Authors:  V Hammarström; K Pauksen; J Azinge; G Oberg; P Ljungman
Journal:  Support Care Cancer       Date:  1993-07       Impact factor: 3.603

9.  Antibody response to pneumococcal vaccine in children receiving bone marrow transplantation.

Authors:  M A Avanzini; A M Carra; R Maccario; M Zecca; P Pignatti; M Marconi; P Comoli; F Bonetti; P De Stefano; F Locatelli
Journal:  J Clin Immunol       Date:  1995-05       Impact factor: 8.317

Review 10.  Pneumococcal polysaccharide vaccines: indications, efficacy and recommendations.

Authors:  G A Bruyn; R van Furth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.